A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results
| العنوان: | A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results |
|---|---|
| المؤلفون: | Gu Mi, David Ferry, J. Yang, Philippe A. Cassier, Emiliano Calvo, Rafael Santana-Davila, Roy S. Herbst, Jose Luis Perez-Gracia, Ian Chau, Johanna C. Bendell, Jessicca Rege, Nicolas Isambert |
| المصدر: | Journal of Clinical Oncology. 34:3056-3056 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | 0301 basic medicine, Cancer Research, Pathology, medicine.medical_specialty, Angiogenesis, business.industry, medicine.medical_treatment, non-small cell lung cancer (NSCLC), Immunosuppression, Pembrolizumab, Gastroesophageal Junction, medicine.disease, Ramucirumab, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Cancer research, medicine, Adenocarcinoma, In patient, business |
| الوصف: | 3056Background: Hallmarks of tumor growth include angiogenesis and immunosuppression. This is the first study to combine R with P to target both processes simultaneously. Preliminary safety results... |
| تدمد: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2016.34.15_suppl.3056 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::99f1c30761acc2b7f57c120b21a62a34 https://doi.org/10.1200/jco.2016.34.15_suppl.3056 |
| رقم الانضمام: | edsair.doi...........99f1c30761acc2b7f57c120b21a62a34 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|---|
| DOI: | 10.1200/jco.2016.34.15_suppl.3056 |